

**Synonym**

BTLA,CD272

**Source**

Biotinylated Human BTLA (31-134), Fc,Avitag (BTA-H82F8) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Thr 134 (Accession # Q7Z6A9).

Predicted N-terminus: Lys 31

**Molecular Characterization**



This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).

The protein has a calculated MW of 40.5 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

**Biotinylation**

*Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.*

**Biotin:Protein Ratio**

The biotin to protein ratio is *0.5-1* as determined by the HABA assay.

**Endotoxin**

Less than 1.0 EU per µg by the LAL method.

**Purity**

>95% as determined by SDS-PAGE.

**Formulation**

Lyophilized from 0.22 µm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

**Reconstitution**

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*

**Storage**


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

*Please avoid repeated freeze-thaw cycles.*

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

**SDS-PAGE**



Biotinylated Human BTLA (31-134), Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

**Bioactivity-ELISA**



Immobilized Human HVEM, Fc Tag (Cat. No. [HVM-H5258](#)) at 10 µg/mL (100 µL/well) can bind Biotinylated Human BTLA (31-134), Fc,Avitag (Cat. No. [BTA-H82F8](#)) with a linear range of 0.3-5 µg/mL (QC tested).

## Background

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

## References

- (1) [Watanabe N., et al., 2003, Nat. Immunol. 4:670-679.](#)
- (2) [Gavrieli M., et al., 2003, Biochem. Biophys. Res. Commun. 312:1236-1243.](#)
- (3) [Sedy J.R., et al., 2005, Nat. Immunol. 6:90-98.](#)

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.